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1214Objective: Although the intra-aortic balloon pump is the most used ventricular assist device, no study has ever
evaluated the best weaning method. We compared 2 different intra-aortic balloon pump weaning methods.
Methods: Thirty consecutive patients needing an intra-aortic balloon pump because of perioperative low-output
cardiac syndrome were randomized to be weaned by ratio (4 consecutive hours of a 1:2 assisting ratio followed
by 1 hour of a 1:3 ratio; group R) or by progressive volume deflation (10% of total volume every hour for 5
consecutive hours; 15 patients, group V). A duration of 5 hours was set a priori as the weaning duration. The
weaning protocol was started when the cardiac index was greater than 2.5 L/min/m2, the central venous pressure
was 12 mmHg or less, the blood lactate was less than 2.5 mmol/L, the mean arterial pressure was greater than 65
mm Hg, and the preserved urine output (1 mL/kg/hr) lasted for at least 5 consecutive hours before weaning.
The cardiac index, indexed systemic vascular resistance, cardiac cycle efficiency, and central venous pressure
were registered at 9 points (T0, start; T1 to T5, the first 5 weaning hours; T6, 2 hours after withdrawal; T7,
12 hours after withdrawal; and T8, at intensive care unit discharge) using the pressure recording analytical
method. The interval from intra-aortic balloon pump withdrawal to intensive care unit discharge, weaning fail-
ure, perioperative troponin I, and lactate (same points) were compared.
Results: All patients, except for 1 belonging to group R (P¼ 1.0), were successfully weaned. Group V had better
preserved cardiac index, indexed systemic vascular resistance, cardiac cycle efficiency, and central venous pressure
(group*time P¼ .0001). Group R had worse cardiac index from T5 to T8 (P .0001), indexed systemic vascular
resistance fromT2 toT8 (P.004), cardiac cycle efficiency fromT3 toT8 (P.001), central venous pressure from
T4 to T8 (P  .0001), and a longer interval from intra-aortic balloon pump withdrawal to intensive care unit
discharge (P ¼ .0001). The lactate level was lower in group V from T5 to T8 (P  .027; group*time P ¼ .001).
Conclusions: Intra-aortic balloon pump weaning by volume deflation allowed better hemodynamic and meta-
bolic parameters. (J Thorac Cardiovasc Surg 2013;145:1214-21)Earn CME credits at
http://cme.ctsnetjournals.org
Since the demonstration in previous decades of the efficacy
of intra-aortic balloon counterpulsation (IABP) in different
conditions of cardiac failure,1-3 its use has widened to
include hemodynamic support in high-risk procedures, re-
fractory unstable angina, acute myocardial infarction and
its complications, low cardiac output syndrome (LCOS),
difficulties in weaning from cardiopulmonary bypass, in-
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The Journal of Thoracic and Cardiovascular Surof the progressive referral of sicker patients for
interventional and surgical procedures, IABP indications
have recently widened further to consider include this
therapy as a prophylactic tool in high-risk procedures.5
Although the exact prevalence of IABP is still far from
assessed, a recent survey estimated its use in 52,000 patients
per year in the United States.6 In 2001, the Benchmark Reg-
istry reported the results of IABP use on more than 16,000
patients, with LCOS the most prevalent indication.3
Although IABP currently represents the first-line left
ventricular assist device in patients with LCOS, no study
has assessed which is the best method to wean a patient
from the IABP of the 2 available methods: volume deflation
or rate reduction. Therefore, it was the aim of the present
pilot study to investigate, for the first time in humans, the he-
modynamic response and leakage of biochemicalmarkers of
myocardial and peripheral ischemia (troponin I and lactate)
using these 2 weaning methods for IABP discontinuation.
METHODS
Patients
From January 2009 to October 2011, of 4390 patients undergoing car-
diac surgery with cardiopulmonary bypass at our institution, 33gery c May 2013
Abbreviations and Acronyms
AMI ¼ acute myocardial infarction
CCE ¼ cardiac cycle efficiency
CI ¼ cardiac index
CVP ¼ central venous pressure
IABP ¼ intra-aortic balloon pump
ICU ¼ intensive care unit
ISVR ¼ indexed systemic vascular resistance
LCOS ¼ low cardiac output syndrome
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cause of LCOS refractory to inotropic or volume support were preliminary
scheduled for enrollment in the present pilot study. Three patients who also
required extracorporeal circulation and membrane oxygenation for pro-
gressive heart failure were eventually excluded. Thus, 30 patients able to
start a weaning trial were finally enrolled.
LCOS was diagnosed in the presence of an inadequate cardiac index
(CI, 2.2 L/min/m2 for>30 minutes); reduced urine output (<1 mL/kg/
hr); metabolic acidosis (elevated serum lactate [>4 mmol/L]) despite ino-
tropic support and adequate correction of preload, afterload, electrolytes,
blood gas abnormalities, and glycemic control; and without evidence of
cardiac tamponade.7
The IABP catheter was always inserted percutaneously, always using
the sheathless technique (8F, 34 or 40 mL according to the patient’s
body surface area; Datascope, Fairfield, NJ) and connected to a Datascope
pump (Datascope). The correct positioning was always assessed by trans-
esophageal echocardiography and confirmed by chest radiography. The
preoperative/intraoperative data, timing, and indications for IABP are re-
ported in Table 1.
Weaning Trial
The duration of the weaning trial was established a priori to last for 5
consecutive hours, according to our traditional institutional policy. The
weaning trial was started when the CI was greater than 2.5 L/min/m2,
the central venous pressure (CVP) was 12 mm Hg or less, the blood lactate
level was less than 2.5 mmol/L, the mean arterial pressure was greater than
65 mmHg, and the preserved urine output (1 mL/kg/hr) lasted for at least
5 consecutive hours. Patients were randomized by lottery to the intensive
care unit (ICU) with 2 different weaning strategies. Fifteen patients (group
R) were randomized to be weaned using the rate-reduction weaning proto-
col, consisting of switching IABP from a 1:1 to a 1:2 electrocardiographic-
coupled assisting ratio for the first 4 consecutive hours and from a 1:2 to
a 1:3 ratio for the last (fifth) hour of the weaning trial, followed by IABP
withdrawal. The other 15 patients (group V) were allocated to the
volume-deflation weaning protocol, consisting of progressive volume de-
flation (10% of the full volume of inflation every hour for 5 consecutive
hours to reach 50% of the total volume of inflation at the end of the trial),
followed by IABP withdrawal.
The weaning trial was stopped and IABP therapy prolonged beyond the
fifth hour in the case of acute hemodynamic instability with signs of re-
newed LCOS. These patients were immediately switched to full IABP as-
sistance (1:1 ratio with full-volume inflation) and considered to have
weaning failure and were withdrawn from the trial.
Hemodynamic Monitoring and Collected Data
The pressure recording analytical method was used for hemodynamic
monitoring and consisted of a beat-by-beat evaluation of the CI, indexed
systemic vascular resistance (ISVR), and cardiac cycle efficiency (CCE),The Journal of Thoracic and Carderived from the arterial-pressure waveform.8,9 The degree of CI changes
during the weaning trial was considered as the primary endpoint of the
study (see the section ‘‘Statistical Analysis’’). The pressure recording
analytical method is based on the mathematical analysis of the arterial
pressure profile changes and has been recently validated for patients with
LCOS and unstable patients undergoing IABP and/or receiving high-
dose inotropic support after cardiac surgery.8 It has been also recognized
as the only less-invasive method able to correlate with the thermodilution
calculations obtained using the Swan-Ganz catheter during IABP and to
compare with the hemodynamic parameters calculated by direct oxygen
Fick method or with transesophageal echocardiography in different hemo-
dynamic conditions.8 From the continuous recording of the arterial-
pressure waveform, the algorithm of the machine computes the CCE,
which provides information about left ventricular wall stress and the heart’s
effort to maintain adequate blood flow and oxygen delivery to the tissues.9
CCE is a nondimensional number ranging from þ1 to negative values.
Positive CCE values represent a better coupling between cardiac function
and energy expenditure (ie, lower left ventricular wall stress). Negative
CCE values represent greater energy expenditure and left ventricular
wall stress.9 Hemodynamic indexes were collected using the pressure re-
cording analytical method at 9 different points (T0, start of the weaning
trial; T1 to T5, the first 5 weaning hours; T6, 2 hours after withdrawal;
T7, 12 hours after withdrawal; and T8, ICU discharge). The CVP was re-
corded at the same points and expressed as millimeters of mercury.
Serum troponin I (monoclonal antibodies; Siemens Medical Solutions
Diagnostics, Terrytown, NY) and lactate (RapidLab1265 AutomaticQC
Cartridge; Siemens Healthcare Italia, Milan, Italy) were measured at the
same 9 points, just as for the hemodynamic indexes. Venous blood for
the detection of troponin I and lactate was always sampled from the distal
line of the central venous catheter.7 The changes in the other hemodynamic
variables and modifications of troponin I and lactate values during the
weaning trial were considered the secondary endpoints of the study.
The prospectively recorded data also included the interval from IABP
withdrawal to ICU discharge, inotropic support or the need for increment
inotropic support after withdrawal, LCOS after withdrawal, the need for re-
institution of IABP after withdrawal, acute myocardial infarction (AMI) af-
ter withdrawal, paroxysmal/persistent atrial fibrillation after withdrawal,
ICU stay, hospital stay, and hospital mortality. Inotropic support was cate-
gorized as none, low (dopamine 5 mg/kg/min), medium (dopamine>5
mg/kg/min and 10 mg/kg/min or dobutamine<5 mg/kg/min), and high
(dopamine >10 mg/kg/min with or without dobutamine>5 mg/kg/min
with or without epinephrine at any dose), according to institutional policy.7
Postwithdrawal LCOSwas defined as a CI of2.2 L/min/m2 for more than
30 minutes with reduced urine output (<1 mL/kg/hr), metabolic acidosis
with elevated serum lactate (>4 mmol/L), despite adequate glycemic con-
trol, without any evidence of cardiac tamponade and despite inotropic sup-
port and adequate correction of preload, afterload, electrolyte, and blood
gas abnormalities.7 Postwithdrawal inotropic support was increased after
IABP discontinuation in the presence of signs of LCOS and titrated on
the hemodynamic indexes. Postwithdrawal LCOS refractory to inotropic
support mandated reinstitution of IABP therapy and was also considered
a weaning failure. Postwithdrawal AMI was defined according to the Euro-
pean Society of Cardiology/American College of Cardiology Foundation/
American Heart Association/World Heart Federation expert consensus
document on the definition of AMI.10 Paroxysmal or persistent atrial fibril-
lation was defined according to the Heart Rhythm Society/European Heart
Rhythm Association/European Cardiac Arrhythmia Society Expert Con-
sensus Statement, as already reported.11 The ICU stay was the days spent
in the ICU. A eupnoeic, extubated patient, with the absence of IABP sup-
port and with stable hemodynamic status (as confirmed by a CI>2.5
L/min/m2, a CVP of 12 mm Hg, a blood lactate level<2.5 mmol/L,
a mean arterial pressure>65 mm Hg, and preserved diuresis of 1 mL/
kg/hr) fulfilled the indication for an ICU discharge. The hospital stay
was the days spent in the hospital after discharge from the ICU.diovascular Surgery c Volume 145, Number 5 1215
TABLE 1. Preoperative and intraoperative data and timing and
indications for IABP
Variable Group V Group R P value
Age (y) 73.2  5.0 74.1  4.3 .616
Male gender 11 (73.3) 9 (60.0) .439
Diabetes mellitus 12 (80.0) 11 (73.3) .666
Hypertension 10 (66.7) 10 (66.7) 1.0
Dyslipidemia 10 (66.7) 8 (53.3) .456
Smoking 11 (73.3) 10 (66.7) .690
COPD 13 (86.7) 12 (80.0) .624
Kidney disease 11 (73.3) 10 (66.7) .690
Logistic euroSCORE 14.1  2.8 13.4  2.9 .498
Preoperative LVEF (%) 37.7  3.0 38.2  4.3 .736
ACC time (min) 94.1  15.7 86.8  15.3 .211
CPB time (min) 154.6  38.2 130.0  36.5 .082
CABG (n) 3.2  0.7 2.8  0.5 .140
Concomitant procedure 13 (86.7) 12 (80.0) .624
Mitral valve surgery 8 (53.3) 8 (53.3) 1.0
Aortic valve surgery 5 (33.3) 3 (20.0) .409
Aortic surgery 2 (13.3) 1 (6.7) .543
IABP timing .456
Intraoperative 8 (53.3) 10 (66.7)
Postoperative 7 (46.7) 5 (33.3)
Indications for IABP .339
Perioperative AMI 3 (20.0) 2 (13.3)
Intraoperative myocardial
stunning
7 (46.7) 4 (26.7)
Difficult weaning from CPB 5 (33.3) 9 (60.0)
COPD was considered present if the patient had at least FEV1/FVC<70% with
FEV150% and<80% of predicted according to the GOLD classification (available
at www.goldcopd.org). Kidney disease was considered present if the patient had at
least an estimated glomerular filtration rate of 60 to 89 mL/min/1.73 m2 according
to the KKDOQI classification (available at www.kdoqi.org). IABP, Intra-aortic bal-
loon pump; V, weaning by progressive volume deflation; R, weaning by progressive
ratio reduction; COPD, chronic obstructive pulmonary disease; euroSCORE, Euro-
pean System for Cardiac Operative Risk Evaluation; LVEF, left ventricular ejection
fraction; ACC, aortic crossclamping; CPB, cardiopulmonary bypass; CABG, coro-
nary artery bypass grafting (distal anastomoses); AMI, acute myocardial infarction;
FEV1/FVC, forced expiratory volume in 1 second/forced vital capacity; KKDOQI,
Kidney Disease Outcomes Quality Initiative.
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and during the entire ICU stay by continuous insulin infusion according to
the Portland protocol.12 The institution’s ethical committee/institutional re-
view board approved the study protocol, and each patient provided in-
formed consent.
Statistical Analysis
The enrollment of 30 patients (15 for each study arm) resulted in 84%
power (1 b error probability) that the study detected a treatment differ-
ence—for the periweaning CI—at a 2-sided .05 significance level, if the
true difference between treatments was at least 20% of the mean of 1 treat-
ment group in terms of the percentile of the mean of the other treatment
group, as previously already reported.13 The partial h2 of the model for
9-time CI measurement was 0.82, with a calculated effect size f of 2.1. Ac-
cordingly, the clinical outcome data should be considered as descriptive only.
The pre- and perioperative data are summarized as the mean standard
deviation or median and 25th to 75th percentile, if continuous, and as
counts and percentages, if categorical. The continuous variables were
tested for normality with the Shapiro-Wilk test and compared between
the 2 treatment groups with the Student t-test or the Mann Whitney
U-test. Categorical variables were compared using the Fisher exact test.1216 The Journal of Thoracic and Cardiovascular SurOrdinal variables were also compared using Mann-Whitney U-test. Re-
peated measures analysis of variance with Bonferroni’s correction for mul-
tiple measurements was used to compare serial data related to troponin I,
lactate release, and the different hemodynamic indexes. Violations of sphe-
ricity were Greenhous-Geisser corrected if ε<0.75 or Huynh-Feldt cor-
rected if ε>0.75. The reported P values include group P, assessing the
level of difference between groups; time P, assessing the change over
time of the measured variables; group*time P, assessing the group–time in-
teraction. Comparisons were considered significant at P<.05, unless dic-
tated otherwise by Bonferroni’s correction. Statistical analysis was
performed using the SPSS program for Windows, version 15.0 (SPSS,
Chicago, Ill).RESULTS
The mean interval from IABP insertion for LCOS and the
start of the weaning trial was comparable in the 2 groups
(group V, 74.8  16.6 hours vs group R, 72.0  15.8 hours;
P ¼ .641).Hemodynamic Response
IABP-induced diastolic pressure augmentation was pre-
served in all the assisted beats during the 1:2 and 1:3 ratios
of the weaning phase in group R. Diastolic augmentation
was always preserved (although attenuated to an extent pro-
portional to the weaning phase) at each step of the entire
weaning trial in all patients in group V.
Both groups started with a similar hemodynamic profile
at the beginning of the weaning trial (T0, P ¼ .616 for CI,
P ¼ .189 for ISVR, P ¼ .393 for CCE, and P ¼ .386 for
CVP; Figures 1 and 2). However, although both groups
maintained a CI greater than 2.5 L/min/m2 during the entire
study period, the CI values were overall greater in group V
than in group R (between-group P ¼ .0001; Figure 1, A),
because of the significantly better values in T5 to T8
(group*time P ¼ .0001; Figure 1, A). Similarly, greater va-
sodilation was achieved by volume deflation (ISVR
between-group P ¼ .0001; Figure 1, B), particularly
because of the significantly lower values for T2 to T8
(group*time P ¼ .0001; Figure 1, B).
The CCE declined at T1 in both groups (Figure 2). How-
ever, given the better CI and ISVR in patients undergoing
volume deflation during the trial and subsequent ICU stay,
hemodynamic monitoring also revealed significantly better
CCE (between-group P ¼ .0001; Figure 2, A), mainly as
a result of the better values for T3 to T8 (group*time,
P ¼ .0001; Figure 2, A). Finally, the CVP was lower in
group V (between-group P ¼ .0001; Figure 2, B) for T4
to T8 (group*time P ¼ .0001; Figure 2, B).Biochemical Results
The troponin I and lactate levels were similar at the be-
ginning of the trial (P ¼ .242 and P ¼ .199, respectively,
at T0; Table 2), and no differences were found in terms
of troponin (between-group P ¼ .715) at any point
(group*time P ¼ .689; Table 2). However, the serum lactategery c May 2013
FIGURE 1. A, Cardiac index (CI) and (B) indexed systemic vascular resistance (ISVR). T0 to T8 as reported in the text. Values are presented as the mean
standard deviation with 95% confidence intervals. Time-point asterisks indicate significant values at single intervals (univariate analysis). V, Weaning by
progressive volume deflation; R, weaning by progressive ratio reduction.
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2), owing to the lower values for T5 to T8 (group*time
P ¼ .001; Table 2).
Clinical Outcomes
One patient in group R (3.3% of the entire study popula-
tion) showed progressive hemodynamic impairment during
theweaning trial at T4 (CI, 2.1 L/min/m2, ISVR, 2212 dyne/FIGURE 2. A, Cardiac cycle efficiency (CCE) and (B) central venous pressure
standard deviation with 95% confidence intervals. Time-point asterisks indicat
progressive volume deflation; R, weaning by progressive ratio reduction.
The Journal of Thoracic and Cars/cm5/m2, CCE,0.21, CVP, 16 mm Hg). This patient re-
quired full IABP assistance until the sixth hour from the
start of weaning. At the sixth hour, a step-down to a 1:2 as-
sist ratio to the eighth hour and to 1:3 for the next hour was
successful (weaning failure in group R, 1/15 [6.7%] and in
group V, 0/15; P ¼ 1.0). Eventually, all patients were suc-
cessfully weaned from IABP, with no need for IABP reinsti-
tution after its withdrawal. No differences were found(CVP). T0 to T8 as reported in the text. Values are presented as the mean
e significant values at single intervals (univariate analysis). V, Weaning by
diovascular Surgery c Volume 145, Number 5 1217
TABLE 2. Biochemical results
T0 T1 T2 T3 T4 T5 T6 T7 T8 Time-P value
Between-group
P value
Troponin I (mg/L)
Group V 5.8  2.1 5.0  0.9 5.1  0.9 4.9  0.9 4.7  1.0 4.4  1.0 4.3  0.9 3.8  1.0 3.3  0.9 .001 .715
Group R 6.5  1.1 5.1  1.3 4.9  1.4 4.8  1.2 4.6  1.2 4.4  1.0 4.2  1.0 4.1  1.0 3.9  0.9 .002
P value* .242 .897 .801 .726 .794 .986 .940 .396 .070 Group*time
P value
.689
Lactate (mmol/L)
Group V 2.3  0.5 2.2  0.7 2.2  0.7 2.1  0.7 2.0  0.7 1.9  0.7 1.5  0.7 1.2  0.5 1.2  0.7 .0001 .002
Group R 2.1  0.5 2.3  1.3 2.3  1.2 2.2  1.2 2.6  0.8 2.8  0.7 2.1  0.6 1.8  0.6 1.8  0.6 .007
P value* .199 .725 .695 .714 .074 .002 .019 .010 .027 Group*time
P value
.001
Data are presented as mean standard deviation. T0 to T8 as reported in the text. V,Weaning by progressive volume deflation; R,weaning by progressive ratio reduction. *Single
points (univariate analysis).
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during the weaning trial (group V, low-dose, 2/15
[13.3%]; medium-dose, 10/15 [66.7%]; high-dose, 3/15
[20.0%] vs group R, low-dose, 3/15 [20.0%], medium-
dose, 8/15 [53.3%], high-dose, 4/15 [28.7%]; P ¼ .753).
One patient in group V (6.7%) and 3 patients in group
R (20.0%; P ¼ .598), however, required postwithdrawal
inotropic augmentation to achieve a satisfactory hemody-
namic profile.
In group R, 2 (13.3%) of 15 patients died in hospital, 1 of
pneumonia and 1 of stroke. No patient in group V died
(P ¼ .483). No postwithdrawal AMI occurred. Postwith-
drawal paroxysmal/persistent atrial fibrillation developed
in 6 patients in group R (40.0%) and 5 patients in group
V (33.3%; P ¼ 1.0).
Patients randomized to progressive volume deflation had
a quicker discharge from the ICU after IABP withdrawal
(18.6  0.6 vs 20.8  1.4 hours in group R; P ¼ .0001).
However, no differences were detected in overall ICU
stay (group V, 7.8  1.9 days vs group R, 9.0  1.7 days;
P ¼ .097) or hospitalization (group V, 17.4  2.7 days vs
group R, 18.3  1.9 days; P ¼ .359). No thrombotic, em-
bolic, hemorrhagic, septic, or vascular complications were
reported.
DISCUSSION
The IABP is the most commonly used left ventricular as-
sist device to manage heart failure, and its use has been fore-
seen to increase owing to the referral of progressively sicker
patients to the ICU.3,6 Despite its worldwide use, however,
to the best of our knowledge, no studies have yet evaluated
which method would be the best to wean a patient from
IABP therapy. This issue is of utmost importance given
the profound effect of LCOS on patient survival, quality
of life, and use of public health resources.7,14
Furthermore, ventricular unloading saves viable myocar-
dium and plays a crucial role in remodeling.15 Accord-
ingly, the weaning phase from IABP therapy should be
seriously planned and interpreted as the last step of the1218 The Journal of Thoracic and Cardiovascular Surmyocardial protective strategy.14 Our study first assessed
the hemodynamic response to 2 different weaning
methods. We found a definitely better hemodynamic pro-
file in patients weaned by progressive volume deflation
compared with those weaned by a reduction of the assist
rate, as demonstrated by the greater degree of vasodilation,
the better CI, the lower oxygen consumption of the myo-
cardium (indirectly derived from the CCE), and the lower
production of peripheral lactate. A recent survey from
Australia showed eclectic approaches to IABP weaning
in different hospitals (eg, isolated rate reduction, isolated
volume deflation, and different combinations of both).16
Isolated rate reduction was found to be the best method
to lessen the incidence of IABP reinstitution and to prevent
the institution/augmentation of inotropic support.16 How-
ever, that study was not targeted to investigate the best
weaning method.16 Furthermore, the absence of standard
weaning protocols and hemodynamic monitoring, the ex-
cessive case mix in terms of indications for IABP (pre-, in-
tra-, and postoperative), and the extreme variability in the
skills and volume of IABP practice in the different centers
significantly affected the results of that study.16 Finally,
these investigators acknowledged that their results were
the consequence of a volume–outcome relationship rather
than dependent on a beneficial hemodynamic effect, with
high-volume centers (more familiar with IABP) generally
using the rate-reduction weaning method.16 The strengths
of our study were the prospective randomized design and
that we studied only the intra- and postoperative IABP
for LCOS (preoperative IABP use was excluded because
of the completely different hemodynamic profile of these
patients). Also, we only included IABP use after cardiac
surgery with cardiopulmonary bypass. Cardiologic or other
clinical scenarios were also excluded because of the com-
pletely different hemodynamic settings. Finally, a strength
of our study was that it was targeted to different hemody-
namic and biochemical parameters to comprehensively
evaluate myocardial performance, cardiac work, and sys-
temic perfusion and metabolism.gery c May 2013
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ter IABP withdrawal by volume deflation, the overall ICU
stay and hospital stay proved comparable in the 2 groups.
This could have been a consequence of the limited number
of patients enrolled (related to the rare occurrence of LCOS
after surgery in current practice). However, although the
differences in ICU stay and overall hospitalization did not
reach statistical significance, group V patients spent an av-
erage of 1 day less in either the ICU or the hospital com-
pared with group R. Both the value of these differences
and their effect on the use of economic resources deserve
future studies.
It is well-known that LCOS has a major influence on mi-
croflow and vascular density, because the smallest vessels
are the principle ones responsible for the altered perfu-
sion.17 Oxygen use is consequently limited by inadequate
transport, leading to increased blood lactate production.17
It has been proved that the greater the lactate levels, the
lower the flow in the microcirculation.18 Furthermore, pre-
vious studies have demonstrated that the microflow changes
induced by cardiogenic shock can be pharmacologically re-
versed,17 suggesting that therapeutic interventions aimed at
opening the microcirculation could be beneficial. It has
been shown that IABP therapy is able to completely reverse
the microflow changes induced by shock, by way of an
endothelial-mediated mechanism, and leading to acute mi-
croflow improvement.18 Thus, our data suggest that pro-
gressive deflation of the balloon volume better preserves
the blood flow in the microcirculation, promoting more ef-
ficient oxygen delivery. Munsterman and colleauges19 in
a recent experimental study of human sublingual microcir-
culation showed that microcirculatory flow paradoxically
increases after stopping the IABP, suggesting an impair-
ment effect of the IABP on microcirculation. It should
be recognized, however, that the study design (1:1 IABP
followed by cyclic cessation) used by Munsterman and
colleagues19 mimics our weaning method using rate
reduction, suggesting that our findings in terms of lactate
leakage could be interpreted as resulting from a hampered
systemic microcirculation achieved using the 1:2 assist
mode. However, it should be acknowledged that the study
byMunsterman and colleagues19 was flawed by the absence
of any hemodynamic monitoring, the extreme variability in
the indications for IABP, and the study design— with IABP
abrupt cessation—not mimicking at all the routine practice
of IABP therapy.19 Finally, the clinical value of sublingual
microcirculation and its correspondence with that of other
organs has been questioned by some studies, showing
how sublingual microflow changes do not directly correlate
with the microflow changes of gut and brain, which can of-
ten be opposite those of the sublingual circulation.20,21
Thus, more studies on this topic are warranted.
We were able to demonstrate that IABP weaning by vol-
ume deflation reduced peripheral lactate leakage. Jung andThe Journal of Thoracic and Carcoworkers18 proved that not, simplistically, the CI, but the
cardiac perfusion index (related to both cardiac perfor-
mance and peripheral perfusion) correlated with circulating
lactate levels. This demonstrated that overall lactate pro-
duction during LCOS is not just of cardiac origin, but rather
the combined result of cardiac dysfunction and altered pe-
ripheral oxygen delivery.18 Similarly, our findings have
confirmed that compared with rate reduction, the volume-
deflation strategy translates into greater peripheral oxygen
delivery and better myocardial metabolism, indicating the
latter method is potentially more physiologic. The better
myocardial metabolism might translate into a greater CI
and CCE, indicating better coupling between cardiac func-
tion and energy expenditure.9 Similar to the cardiac perfu-
sion index of the study by Jung and colleagues,18 the
lower myocardial oxygen consumption (CCE) and the
greater peripheral perfusion (ISVR) translated into lower
serum lactate leakage in group V.
It is also noteworthy that an evident decline of the CCE
was already present at T1 in both groups, although this was
subsequently attenuated by the volume-deflation strategy.
An elegant in vivo study has already demonstrated that
IABP reduced myocardial oxygen demand and improved
distal perfusion owing to the augmentation of aortic ela-
stance.22 Similarly, the IABP induces an augmentation of
stroke work, a reduction of myocardial oxygen demand,
decreased systemic vascular resistance, and aortic imped-
ance.23 Bia and colleagues24 and Cabrera-Fischer and col-
leagues25 showed that the IABP has a direct vasodilative
effect on the smooth muscle cells. A direct endothelium-
dependent vasoactive effect has also been shown on small
and medium arterioles26 and at a microvascular level.18
According to these peripheral effects of IABP, the lower
ISVR in group V of our study suggested maintenance dur-
ing the weaning period of the vasodilative effect of the bal-
loon, with more pronounced vascular effects with the
volume-deflation weaning method. Finally, a recent human
study evaluated the balloon compression flow wave (during
inflation) and its expansion flow wave (during deflation)
with a 1:1 or 1:2 assist ratio and correlated them to dia-
stolic aortic pressure augmentation and reduction.27 The
investigators found that the diastolic aortic pressure aug-
mentation was greater during the 1:1 ratio and end-
diastolic aortic pressure reduction decreased during the
1:1 ratio but was unchanged during the 1:2 ratio.27 The en-
ergy of the compression wave correlated positively with
the diastolic pressure augmentation and the energy of the
expansion wave correlated negatively with the end-
diastolic aortic pressure reduction only with the 1:1 assist
ratio.27 In contrast, these relationships were unchanged
during the 1:2 ratio.27 All these data demonstrated that
1:2 IABP therapy does not result in any hemodynamic ben-
efit.27 The results of our study similarly suggested that
switching an IABP to the 1:2 ratio simply correspondeddiovascular Surgery c Volume 145, Number 5 1219
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abrupt cessation of IABP therapy.
From the results of our study, it could be speculated that
the rate-reduction weaning method might be hazardous
early after LCOS. However, the progressive volume
deflation—with its better preserved hemodynamic pro-
file—appears to reduce the IABP assist properties more
gradually, aiding the healing ventricle to undergo a more
physiologic weaning trial.
Study Limitations
Themain limitationof the present studywas the small sam-
ple size (resulting from the preliminary nature of the trial),
significantly limiting the clinical significance of the reported
differences in hemodynamic and biochemical outcome vari-
ables. It also reflects the current low incidence of severe post-
cardiotomyLCOS requiring IABP therapy. Finally, our study
was a single-center design, although that guaranteed the
uniformity of the perioperative management of the patient
population and strict adherence to the planned protocol.
The present study lacked pure cardiologic indications for
IABP (eg, AMI in the setting of an ICU) outside the cardiac
surgery scenarios. Therefore, our patients could presumably
have benefited from the surgical relief of myocardial ische-
mia and/or of hemodynamic compromise caused by the un-
derlying valve disease. Thus, the IABP weaning in our
series might have incorporated some physiologic improve-
ments unrelated to the sole IABP. Although our data cannot
be directly extrapolated to different clinical scenarios, the
results represent the first comparison with hemodynamic
monitoring of 2 different weaning modalities in the postop-
erative phase of cardiac surgical practice.
The similar clinical outcomes obtained with the 2 tech-
niques might suggest that both IABP weaning methods
can be considered effective if a patient has been adequately
supported and allowed to recover. However, the results of
the present study highlight how different the hemodynamic
and biochemical responses to the 2 weaning methods can be
(despite an apparently comparable and uncomplicated clin-
ical outcome). The better hemodynamic indexes and lower
peripheral lactate leakage after progressive volume defla-
tion might suggest a new thinking in the approach to the
IABP weaning phase. More studies with a larger number
of patients are necessary to investigate the actual clinical ef-
fect of these 2 different strategies.
Another limitation was related to the absence of objective
data precisely quantifying the entity of progressive volume
deflation at each cycle. The IABP console has been vali-
dated for progressive volume deflation in clinical practice,
and internal safety systems are able to continuously monitor
the inner volume of the entire circuit and to quantify the vol-
ume of inflation and deflation for each cardiac cycle. How-
ever, experimental models with peripheral flow meters or
magnetic resonance imaging studies with computational1220 The Journal of Thoracic and Cardiovascular Surmodels measuring the degree of displaced blood volume
for each IABP cycle are probably needed to better quantify
the volume deflation weaning method.
A final limitation was the absence of standardized IABP
weaning methods in the current data to which refer for our
study design and method. Therefore, ethical issues led us to
use the only 2 available IABP weaning methods, to adhere
to our traditional institutional policies, and to prospectively
randomize patients to 1 of these 2 methods. From a different
perspective, these limitations could be considered as
strengths of our study. This is because it is first prospective
randomized trial to evaluate the best IABP weaning method
using a comprehensive biochemical, hemodynamic, and
clinical outcome analysis for a select cohort of patients
with postcardiotomy LCOS. This also excluded patients un-
dergoing prophylactic preoperative IABP. The results of the
present study deserve future investigations to better define
the role of different IABP weaning methods on subtle mi-
crovascular flow changes, different scenarios (eg, prophy-
lactic IABP), different organ function, and so on.
CONCLUSIONS
The preliminary results of our pilot study seem to suggest
that IABP weaning using progressive volume deflation
should be preferred to the traditional rate reduction because
of the better hemodynamic and metabolic profiles, as shown
by the better CI, greater degree of vasodilation, lower oxy-
gen consumption of the myocardium (indirectly derived
from the CCE), and lower production of peripheral lactate.
Despite the apparently similar and satisfactory clinical out-
comes, the hemodynamic and biochemical responses to the
2 weaning protocols proved to be completely different. The
volume-deflation method was a gradual and slower ap-
proach to IABP weaning, and the rate-reduction method re-
sulted in abrupt IABP cessation, with the potential to harm
a recently healed ventricle.
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